Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Alzheimers Dis ; 83(1): 57-63, 2021.
Article in English | MEDLINE | ID: mdl-34250937

ABSTRACT

BACKGROUND: Possible benefits of makeup therapy, in terms of immediate and late effects on cognitive and affective functions, have not been fully proved for dementia patients. OBJECTIVE: To evaluate the immediate effect of makeup therapy on dementia patients. METHODS: Female nursing home residents with dementia received either only skin care treatment (control group, n = 17) or skin care plus makeup therapy treatment (makeup therapy group, n = 19). Cognitive, affective, and activity of daily living (ADL) scores were evaluated before and just after treatments. Apparent age and emotion were also evaluated with artificial intelligence (AI) software. RESULTS: Makeup therapy significantly improved Abe's behavioral and psychological symptoms of dementia (BPSD) score (ABS, *p < 0.05). AI software judged that makeup therapy significantly made the apparent age younger (*p < 0.05). In particular, patients with moderate ADL scores had a significantly higher happiness score in makeup therapy (*p < 0.05), with a modest correlation to the Mini-Mental State Examination (MMSE, r = 0.42, *p < 0.05). The severe baseline MMSE group reported a greater feeling of satisfaction following makeup therapy (*p < 0.05). CONCLUSION: The present makeup therapy is a promising non-pharmacological approach to immediately alleviate BPSD in female dementia patients, and the present AI software quickly and quantitatively evaluated the beneficial effects of makeup therapy on facial appearance.


Subject(s)
Artificial Intelligence , Automated Facial Recognition , Beauty , Behavioral Symptoms , Dementia/therapy , Skin Care , Activities of Daily Living/psychology , Aged, 80 and over , Dementia/psychology , Female , Humans , Mental Status and Dementia Tests/statistics & numerical data , Nursing Homes , Patient Satisfaction , Psychiatric Status Rating Scales/statistics & numerical data , Software
2.
J Alzheimers Dis ; 71(3): 1063-1069, 2019.
Article in English | MEDLINE | ID: mdl-31476161

ABSTRACT

Oxidative stress is part of the entire pathological process that underlies the development of Alzheimer's disease (AD), including the mild cognitive impairment (MCI) stage. Twendee X (TwX) is a supplement containing a strong antioxidative mix of eight antioxidants, which has been shown to have a clinical and therapeutic benefit in AD model mice. Here, we conducted a multicenter, randomized, double-blind, and placebo-controlled prospective interventional study to evaluate the efficacy of TwX in mitigating MCI. The primary outcomes were differences in Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale-revised (HDS-R) scores between baseline and six months for placebo and TwX groups. Seventy-eight subjects with MCI were randomized into placebo (n = 37) and TwX (n = 41) groups. MMSE scores at six months differed significantly between the TwX and placebo groups (p = 0.018), and HDS-R scores for the TwX group exhibited a significant improvement at six months relative to baseline (p = 0.025). The TwX group did not show any change in affective or activities of daily living scores at six months. The present study indicates that strong antioxidative supplement TwX is clinical beneficial for cognitive function in subjects with MCI.


Subject(s)
Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Cognitive Dysfunction/drug therapy , Cystine/therapeutic use , Dietary Supplements , Glutamine/therapeutic use , Activities of Daily Living , Aged , Aged, 80 and over , Cognition , Cognitive Dysfunction/psychology , Double-Blind Method , Female , Humans , Male , Mental Status and Dementia Tests , Prospective Studies , Treatment Outcome
3.
Biol Pharm Bull ; 40(3): 284-289, 2017 Mar 01.
Article in English | MEDLINE | ID: mdl-28003606

ABSTRACT

We investigated the solubility of 10 samples of sucrose esters of fatty acids (SEFA) products that are commercially available worldwide as food additives (emulsifiers). Although one sample dissolved transparently in both water and ethanol, other samples produced white turbidity and/or precipitates and did not meet the solubility criterion established by the Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Expert Committee on Food Additives (JECFA). When the sample solutions were heated, the solubility in both water and ethanol increased. All of the samples dissolved transparently in ethanol, and dispersed and became white without producing precipitates in water. The present study suggests that the current solubility criterion of the JECFA SEFA specifications needs to be revised.


Subject(s)
Emulsifying Agents/chemistry , Esters/chemistry , Fatty Acids/chemistry , Food Additives/chemistry , Sucrose/chemistry , Ethanol , Humans , Reference Standards , Solubility , Solutions , United Nations , Water , World Health Organization
SELECTION OF CITATIONS
SEARCH DETAIL